Repression of vascular endothelial growth factor expression by the runt-related transcription factor 1 in acute myeloid leukemia

Cancer Research

Volumn 71, Issue 7, 2011, Pages 2761-2771

  Elst, Arja Ter ^a   Ma, Bin ^a   Scherpen, Frank J G ^a   De Jonge, Hendrik J M ^a   Douwes, Jenny ^a   Wierenga, Albertus T J ^b   Schuringa, Jan Jacob ^b   Kamps, Willem A ^a   De Bont, Eveline S J M ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; TRANSCRIPTION FACTOR RUNX1; VASCULOTROPIN A;

ACUTE GRANULOCYTIC LEUKEMIA; AML1 GENE; ARTICLE; BINDING SITE; BLAST CELL; CHROMOSOME TRANSLOCATION 21; CHROMOSOME TRANSLOCATION 8; CONTROLLED STUDY; GENE; GENE ACTIVITY; GENE EXPRESSION REGULATION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN PROTEIN INTERACTION; UPREGULATION; VEGFA GENE;

BINDING SITES; CELL LINE, TUMOR; CHROMOSOMES, HUMAN, PAIR 21; CHROMOSOMES, HUMAN, PAIR 8; CORE BINDING FACTOR ALPHA 2 SUBUNIT; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; GENE SILENCING; HL-60 CELLS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MUTATION; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS; RNA, MESSENGER; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TRANSLOCATION, GENETIC; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79953294156     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-0402     Document Type: Article

References (49)

1. Aguayo A, Estey E, Kantarjian H, Mansouri T, Gidel C, Keating M, et al. Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood 1999;94:3717-21.
2. Padro T, Bieker R, Ruiz S, Steins M, Retzlaff S, Bürger H, et al. Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia. Leukemia 2002;16:1302-10.
3. de Bont ES, Fidler V, Meeuwsen T, Scherpen F, Hählen K, Kamps WA. Vascular endothelial growth factor secretion is an independent prognostic factor for relapse-free survival in pediatric acute myeloid leukemia patients. Clin Cancer Res 2002;8:2856-61. (Pubitemid 35025730)
4. Dias S, Hattori K, Zhu Z, Heissig B, Choy M, Lane W, et al. Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. J Clin Invest 2000;106:511-21. (Pubitemid 30666384)
5. Dias S, Hattori K, Heissig B, Zhu Z, Wu Y, Witte L, et al. Inhibition of both paracrine and autocrine VEGF/ VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias. Proc Natl Acad Sci U.S.A 2001;98:10857-62. (Pubitemid 32878709)
6. Bellamy WT, Richter L, Sirjani D, Roxas C, Glinsmann-Gibson B, Frutiger Y, et al. Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Blood 2001;97:1427-34. (Pubitemid 32183769)
7. Santos SC, Dias S. Internal and external autocrine VEGF/KDR loops regulate survival of subsets of acute leukemia through distinct signaling pathways. Blood 2004;103:3883-9. (Pubitemid 38596309)
8. Brogi E, Wu T, Namiki A, Isner JM. Indirect angiogenic cytokines upregulate VEGF and bFGF gene expression in vascular smooth muscle cells, whereas hypoxia upregulates VEGF expression only. Circulation 1994;90:649-52. (Pubitemid 24242728)
9. Wojta J, Kaun C, Breuss JM, Koshelnick Y, Beckmann R, Hattey E, et al. Hepatocyte growth factor increases expression of vascular endothelial growth factor and plasminogen activator inhibitor-1 in human keratinocytes and the vascular endothelial growth factor receptor flk-1 in human endothelial cells. Lab Invest 1999;79:427-38. (Pubitemid 29190432)
10. Ko Y, Totzke G, Gouni-Berthold I, Sachinidis A, Vetter H. Cytokine-inducible growth factor gene expression in human umbilical endothelial cells. Mol Cell Probes 1999;13:203-11. (Pubitemid 29312896)
11. Brizzi MF, Formato L, Dentelli P, Rosso A, Pavan M, Garbarino G, et al. Interleukin-3 stimulates migration and proliferation of vascular smooth muscle cells: a potential role in atherogenesis. Circulation 2001;103:549-54. (Pubitemid 32116240)
12. Wei LH, Kuo ML, Chen CA, Chou CH, Lai KB, Lee CN, et al. Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway. Oncogene 2003;22:1517-27.
13. Rak J, Mitsuhashi Y, Bayko L, Filmus J, Shirasawa S, Sasazuki T, et al. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res 1995;55:4575-80.
14. Mukhopadhyay D, Tsiokas L, Zhou XM, Foster D, Brugge JS, Sukhatme VP. Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation. Nature 1995;375:577-81.
15. Ryuto M, Ono M, Izumi H, Yoshida S, Weich HA, Kohno K, et al. Induction of vascular endothelial growth factor by tumor necrosis factor alpha in human glioma cells. Possible roles of SP-1. J Biol Chem 1996;271:28220-8. (Pubitemid 26374633)
16. Shih SC, Claffey KP. Role of AP-1 and HIF-1 transcription factors in TGF-beta activation of VEGF expression. Growth Factors 2001;19:19-34. (Pubitemid 32970678)
17. Wei D, Le X, Zheng L, Wang L, Frey JA, Gao AC, et al. Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. Oncogene 2003;22:319-29. (Pubitemid 36194328)
18. Erickson P, Gao J, Chang KS, Look T, Whisenant E, Raimondi S, et al. Identification of breakpoints in t(8;21) acute myelogenous leukemia and isolation of a fusion transcript, AML1/ETO, with similarity to Drosophila segmentation gene, runt. Blood 1992;80:1825-31.
19. Morishita K, Parganas E, Bartholomew C, Sacchi N, Valentine MB, Raimondi SC, et al. The human Evi-1 gene is located on chromosome 3q24-q28 but is not rearranged in three cases of acute nonlymphocytic leukemias containing t(3;5)(q25;q34) translocations. Oncogene Res 1990;5:221-31. (Pubitemid 20088245)
20. Osato M. Point mutations in the RUNX1/AML1 gene: another actor in RUNX leukemia. Oncogene 2004;23:4284-96. (Pubitemid 38765137)
21. Taketani T, Taki T, Takita J, Tsuchida M, Hanada R, Hongo T, et al. AML1/RUNX1 mutations are infrequent, but related to AML-M0, acquired trisomy 21, and leukemic transformation in pediatric hematologic malignancies. Genes Chromosomes.Cancer 2003;38:1-7. (Pubitemid 36994878)
22. Harada Y, Harada H. Molecular pathways mediating MDS/AML with focus on AML1/RUNX1 point mutations. J Cell Physiol 2009;220:16-20.
23. Blyth K, Cameron ER, Neil JC. The RUNX genes: gain or loss of function in cancer. Nat Rev Cancer 2005;5:376-87. (Pubitemid 40637829)
24. Okuda T, van DJ, Hiebert SW, Grosveld G, Downing JR. AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell 1996;84:321-30. (Pubitemid 26042836)
25. Miller J, Horner A, Stacy T, Lowrey C, Lian JB, Stein G, et al. The core-binding factor beta subunit is required for bone formation and hematopoietic maturation. Nat Genet 2002;32:645-49. (Pubitemid 35435178)
26. Durst KL, Hiebert SW. Role of RUNX family members in transcriptional repression and gene silencing. Oncogene 2004;23:4220-4. (Pubitemid 38758587)
27. Sun W, Downing JR. Haploinsufficiency of AML1 results in a decrease in the number of LTR-HSCs while simultaneously inducing an increase in more mature progenitors. Blood 2004;104:3565-72. (Pubitemid 39564428)
28. Ichikawa M, Asai T, Saito T, Seo S, Yamazaki I, Yamagata T, et al. AML-1 is required for megakaryocytic maturation and lymphocytic differentiation, but not for maintenance of hematopoietic stem cells in adult hematopoiesis. Nat Med 2004;10:299-304. (Pubitemid 38667622)
29. Yokomizo T, Ogawa M, Osato M, Kanno T, Yoshida H, Fujimoto T, et al. Requirement of Runx1/AML1/PEBP2alphaB for the generation of haematopoietic cells from endothelial cells. Genes Cells 2001;6:13-23. (Pubitemid 32156750)
30. Ahn MY, Huang G, Bae SC, Wee HJ, Kim WY, Ito Y. Negative regulation of granulocytic differentiation in the myeloid precursor cell line 32Dcl3 by ear-2, a mammalian homolog of Drosophila seven-up, and a chimeric leukemogenic gene, AML1/ETO. Proc Natl Acad Sci U.S.A 1998;95:1812-17.
31. Hiramatsu A, Miwa H, Shikami M, Ikai T, Tajima E, Yamamoto H, et al. Disease-specific expression of VEGF and its receptors in AML cells: possible autocrine pathway of VEGF/type1 receptor of VEGF in t(15;17) AML and VEGF/type2 receptor of VEGF in t(8;21) AML. Leuk Lymphoma 2006;47:89-95. (Pubitemid 43101730)
32. Valk PJ, Verhaak RG, Beijen MA, Erpelinck CA, Barjesteh van Waalwijk van Doorn-Khosrovani S, Boer JM, et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med 2004;350:1617-28. (Pubitemid 38528701)
33. de Jonge HJ, de Bont ES, Valk PJ, Schuringa JJ, Kies M, Woolthuis CM, et al. AML at older age: age-related gene expression profiles reveal a paradoxical down-regulation of p16INK4A mRNA with prognostic significance. Blood 2009;114:2869-77.
34. Liu D, Jia H, Holmes DI, Stannard A, Zachary I. Vascular endothelial growth factor-regulated gene expression in endothelial cells: KDR-mediated induction of Egr3 and the related nuclear receptors Nur77, Nurr1, and Nor1. Arterioscler.Thromb Vasc Biol 2003;23:2002-7. (Pubitemid 37433192)
35. Morgenstern JP, Land H. Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res 1990;18:3587-96.
36. Kustikova OS, Wahlers A, Kuhlcke K, Stahle B, Zander AR, Baum C, et al. Dose finding with retroviral vectors: correlation of retroviral vector copy numbers in single cells with gene transfer efficiency in a cell population. Blood 2003;102:3934-37. (Pubitemid 37486973)
37. Wildonger J, Mann RS. The t(8;21) translocation converts AML1 into a constitutive transcriptional repressor. Development 2005;132:2263-72. (Pubitemid 40872797)
38. Zelzer E, Glotzer DJ, Hartmann C, Thomas D, Fukai N, Soker S, et al. Tissue specific regulation of VEGF expression during bone development requires Cbfa1/Runx2. Mech Dev 2001;106:97-106. (Pubitemid 32701077)
39. Sun X, Wei L, Chen Q, Terek RM. HDAC4 represses vascular endothelial growth factor expression in chondrosarcoma by modulating RUNX2 activity. J Biol Chem 2009;284:21881-90.
40. Javed A, Barnes GL, Pratap J, Antkowiak T, Gerstenfeld LC, van Wijnen AJ, et al. Impaired intranuclear trafficking of Runx2 (AML3/CBFA1) transcription factors in breast cancer cells inhibits osteolysis in vivo. Proc Natl Acad Sci U S A 2005;102:1454-9. (Pubitemid 40209191)
41. Peng Z, Wei D, Wang L, Tang H, Zhang J, Le X, et al. RUNX3 inhibits the expression of vascular endothelial growth factor and reduces the angiogenesis, growth, and metastasis of human gastric cancer. Clin Cancer Res 2006;12:6386-94. (Pubitemid 44799709)
42. Tanaka K, Tanaka T, Kurokawa M, Imai Y, Ogawa S, Mitani K, et al. The AML1/ETO(MTG8) and AML1/Evi-1 leukemia-associated chimeric oncoproteins accumulate PEBP2beta(CBFbeta) in the nucleus more efficiently than wild-type AML1. Blood 1998;91:1688-99. (Pubitemid 28110334)
43. Yergeau DA, Hetherington CJ, Wang Q, Zhang P, Sharpe AH, Binder M, et al. Embryonic lethality and impairment of haematopoiesis in mice heterozygous for an AML1-ETO fusion gene. Nat Genet 1997;15:303-6. (Pubitemid 27098728)
44. Okuda T, Cai Z, Yang S, Lenny N, Lyu CJ, van Deursen JM, et al. Expression of a knocked-in AML1-ETO leukemia gene inhibits the establishment of normal definitive hematopoiesis and directly generates dysplastic hematopoietic progenitors. Blood 1998;91:3134-43. (Pubitemid 28193861)
45. Tang JL, Hou HA, Chen CY, Liu CY, Chou WC, Tseng MH, et al. AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations. Blood 2009;114:5352-61.
46. Silva FP, Swagemakers SM, Erpelinck-Verschueren C, Wouters BJ, Delwel R, Vrieling H, et al. Gene expression profiling of minimally differentiated acute myeloid leukemia: M0 is a distinct entity subdivided by RUNX1 mutation status. Blood 2009;114:3001-7.
47. Suehiro J, Hamakubo T, Kodama T, Aird WC, Minami T. Vascular endothelial growth factor activation of endothelial cells is mediated by early growth response-3. Blood 2010;115:2520-32.
48. Imai N, Shikami M, Miwa H, Suganuma K, Hiramatsu A, Watarai M, et al. t(8;21) acute myeloid leukaemia cells are dependent on vascular endothelial growth factor (VEGF)/VEGF receptor type2 pathway and phosphorylation of Akt. Br J Haematol 2006;135:673-82. (Pubitemid 44674078)
49. Imai N, Miwa H, Shikami M, Suganuma K, Gotoh M, Hiramatsu A, et al. Growth inhibition of AML cells with specific chromosome abnormalities by monoclonal antibodies to receptors for vascular endothelial growth factor. Leuk Res 2009;33:1650-7.